Spots Global Cancer Trial Database for recurrent bladder urothelial carcinoma

Every month we try and update this database with for recurrent bladder urothelial carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma	NCT03513952	Advanced Bladde... Advanced Ureter... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur...	Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Glycosylated Re... Laboratory Biom... Magnetic Resona... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy	NCT04963153	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr...	Biospecimen Col... Computed Tomogr... Enfortumab Vedo... Erdafitinib	18 Years -	National Cancer Institute (NCI)
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression	NCT04953104	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... Unresectable Ur...	Diagnostic Labo... Nivolumab Relatlimab	18 Years -	M.D. Anderson Cancer Center
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression	NCT04953104	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... Unresectable Ur...	Diagnostic Labo... Nivolumab Relatlimab	18 Years -	M.D. Anderson Cancer Center
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer	NCT00749892	Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Stage 0a Bladde... Stage 0a Renal ... Stage 0a Ureter... Stage 0a Urethr... Stage 0is Bladd... Stage 0is Renal... Stage 0is Urete... Stage 0is Ureth... Stage II Bladde... Stage II Renal ... Stage II Ureter... Stage II Urethr... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad...	Erlotinib Hydro...	19 Years -	M.D. Anderson Cancer Center
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer	NCT00749892	Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Stage 0a Bladde... Stage 0a Renal ... Stage 0a Ureter... Stage 0a Urethr... Stage 0is Bladd... Stage 0is Renal... Stage 0is Urete... Stage 0is Ureth... Stage II Bladde... Stage II Renal ... Stage II Ureter... Stage II Urethr... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad...	Erlotinib Hydro...	19 Years -	M.D. Anderson Cancer Center
Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer	NCT02718742	Recurrent Bladd... Stage IV Bladde...	Laboratory Biom... Paclitaxel Albu... Quality-of-Life...	18 Years -	Mayo Clinic
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression	NCT04953104	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... Unresectable Ur...	Diagnostic Labo... Nivolumab Relatlimab	18 Years -	M.D. Anderson Cancer Center
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression	NCT04953104	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... Unresectable Ur...	Diagnostic Labo... Nivolumab Relatlimab	18 Years -	M.D. Anderson Cancer Center
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer	NCT03237780	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur...	Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Eribulin Mesyla...	18 Years -	National Cancer Institute (NCI)
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer	NCT03237780	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur...	Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Eribulin Mesyla...	18 Years -	National Cancer Institute (NCI)
Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer	NCT04496219	Bladder Urothel... Recurrent Bladd... Stage 0a Bladde... Stage 0is Bladd... Stage I Bladder... Superficial Bla...	Acupuncture The... BCG Solution Best Practice Quality-of-Life... Questionnaire A...	18 Years -	Fred Hutchinson Cancer Center
Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer	NCT02718742	Recurrent Bladd... Stage IV Bladde...	Laboratory Biom... Paclitaxel Albu... Quality-of-Life...	18 Years -	Mayo Clinic

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: